🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

IPO prospects 'dampened' by further market decline, says Pitchbook

Published 25/10/2023, 14:37
IPO prospects 'dampened' by further market decline, says Pitchbook
NDX
-
USD/GBP
-
IXIC
-

Proactive Investors - Public market debut prospects “are dampened by further market decline and higher rates”, according to new research from Morningstar data firm Pitchbook Data Inc.

It said that successful initial public offerings (IPOs) “will be slightly harder to achieve” at robust valuations given the recent decline in public market valuations.

The report cited market debuts by Instacart (NASDAQ:CART) and Birkenstock, which it said have “underperformed” relative to their pre-IPO valuations, for example Instacart’s private market valuation of US$39 billion fell to US$9.9 billion after its recent debut on the stock market.

IPOs are being suppressed by "decelerating revenue growth", which Pitchbook analysts said is making it take longer for start-ups to grow into the elevated valuations seen in 2020 and 2021.

The report said that late-stage investors are wary of pushing portfolio companies to list their shares on the public markets, and that venture capitalists will “likely recoup more capital” if they wait for companies to grow into their valuations.

“It will take some companies several years to grow into their valuations, and some may never succeed,” Pitchbook analysts said in the report.

Nasdaq is down 5.7% as of 17 October compared to its peak after the Federal Reserve signalled higher interest rates will last for longer, the report said.

“Market corrections typically hit fast-growth companies harder,” Pitchbook analysts warned.

Birkenstock performed negative 15.1% compared to Nasdaq to 17 October, its data showed, while Instacart (NASDAQ:CART) was negative 17.2% compared to Nasdaq.

But performance has been mixed across the biggest seven US IPOs of the past four months, with Arm Holdings PLC (NASDAQ:ARM), Klaviyo (NYSE:KVYO), RayzeBio and CAVA all performing better than Nasdaq, it said, with CAVA up 61.2% compared to the exchange average data during the period.

Read more on Proactive Investors UK

Disclaimer

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.